Author

D. B. Krastev

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Approach:genetic perturbation / CRISPR· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

C. J. Lord· 3 shared F. Song· 2 shared R. Brough· 2 shared S. J. Pettitt· 2 shared A. Ashworth· 1 shared A. Drean· 1 shared A. Gulati· 1 shared A. Legrand· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. J. Lord

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

PARP inhibitors enhance reovirus-mediated cell killing through the death-inducing signaling complex (DISC) with an associated NF-kappa B-regulated immune response.

J. Kyula-Currie, V. Roulstone, J. Wright, F. Butera, A. Legrand, R. Elliott, M. McLaughlin, G. Bozhanova, D. B. Krastev, S. Pettitt, T. Tenev, M. T. B. Dillon, S. Foo, E. C. Patin, V. Jennings, , K. J. Harrington

This paper identifies PARP inhibitors as sensitizers for oncolytic reovirus by enhancing DISC-mediated apoptosis and NF-kappa B-driven immune responses.

bioRxiv · Dec 21, 2023 · PreprintCancer Biology

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

A. Zelceski, P. Francica, L. Lingg, M. Mutlu, C. Stok, M. Liptay, J. Alexander, J. S. Baxter, R. Brough, A. Gulati, S. Haider, M. Raghunandan, F. Song, S. Sridhar, J. V. Forment, , C. J. Lord

This study shows that PSMC3IP and MND1 depletion increases PARP inhibitor sensitivity in mitotic cells through impaired D-loop formation and homology-directed repair.

bioRxiv · Aug 24, 2022Cancer Biology

USP28 and SPINT2 mediate cell cycle arrest after whole genome doubling

Z. Storchova, K. Seget-Trzensiok, S. V. Bernhard, C. Kuffer, D. B. Krastev, M. Theiss, K. Keuper, J.-E. Boekenkamp, M. Kschischo, F. Buchholz

The paper identifies USP28 and SPINT2 as factors that enable tetraploid cell survival by modulating cell cycle arrest and DNA damage responses.

bioRxiv · Sep 18, 2020 · PreprintCell Biology

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

S. J. Pettitt, D. B. Krastev, I. Brandsma, A. Drean, F. Song, R. Aleksandrov, M. I. Harrell, M. Menon, R. Brough, J. Campbell, J. Frankum, M. Ranes, H. N. Pemberton, R. Rafiq, K. Fenwick, , C. J. Lord

The paper identifies PARP1 point mutations causing PARP inhibitor resistance through CRISPR-Cas9 screens and shows their impact on PARP1 trapping and chemotherapy sensitivity.

bioRxiv · Oct 14, 2017Cancer Biology